Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Solid Organ Transplantation

Conditions:   Allosensitization;   Heart Transplant Failure and Rejection Intervention:   Drug: Daratumumab Sponsor:   Ronald Witteles Not yet recruiting

Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials